Celltrion traded at 199,400.00 this Monday March 30th, decreasing 6,600.00 or 3.20 percent since the previous trading session. Looking back, over the last four weeks, Celltrion lost 11.38 percent. Over the last 12 months, its price rose by 17.99 percent. Looking ahead, we forecast Celltrion to be priced at 194,979.00 by the end of this quarter and at 165,329.25 in one year, according to Trading Economics global macro models projections and analysts expectations.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.